A. Diehl

Epidemiology · 2000–2018

A researcher in the Science corpus: 14 papers; trusts 2 researchers and is trusted by 4 researchers here, as inferred from the citation graph.

Subfields

Epidemiology — 157 citations into it; #841 of 2,148 by trust here, #94 by citations
Hepatology — 85 citations into it; #83 of 151 by trust here, #23 by citations

Whom A. Diehl trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

Z. Younossi

Who trusts A. Diehl overall

Papers from A. Diehl's perspective

Ordered by how strongly the researchers A. Diehl trusts endorse each paper. Same corpus, a different order for every researcher.

ENDPOINTS AND CLINICAL TRIAL DESIGN FOR NONALCOHOLIC STEATOHEPATITIS (Hepatology)
The prevalence and etiology of elevated aminotransferase levels in the United States (American Journal of Gastroenterology)
Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. (New England Journal of Medicine)
Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults (Alimentary Pharmacology and Therapeutics)
Meta‐analysis of the influence of I148M variant of patatin‐like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease (Hepatology)
Histopathology of pediatric nonalcoholic fatty liver disease (Hepatology)
Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement (Current Opinion in Cardiology)
In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease (Hepatology)
Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. (Clinical Gastroenterology and Hepatology)
Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers (Hepatology)

Their papers

Metformin reverses fatty liver disease in obese, leptin-deficient mice (2000) — 700 citations
The severity of NAFLD is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota (2016) — 1,287 citations
Fructose and Sugar: A Major Mediator of Nonalcoholic Fatty Liver Disease (2018) — 805 citations
Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis (2017) — 1,080 citations
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial (2014) — 2,063 citations
NAFLD, NASH and liver cancer (2013) — 966 citations
The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association (2012) — 2,216 citations
The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. (2012) — 1,723 citations
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis (2010) — 3,032 citations
Fructose consumption as a risk factor for non-alcoholic fatty liver disease. (2008) — 829 citations
Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis (2007) — 1,024 citations
The prevalence and etiology of elevated aminotransferase levels in the United States (2003) — 1,413 citations
Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease (2003) — 948 citations
Cytokines in alcoholic and nonalcoholic steatohepatitis. (2000) — 978 citations